File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

TitleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
Authors
KeywordsASP-1
H5N1
M2e
Vaccine
Issue Date2010
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2010, v. 28 n. 44, p. 7233-7240 How to Cite?
AbstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/135278
ISSN
2014 Impact Factor: 3.624
2014 SCImago Journal Rankings: 1.740
ISI Accession Number ID
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorZhao, Gen_HK
dc.contributor.authorDu, Len_HK
dc.contributor.authorXiao, Wen_HK
dc.contributor.authorSun, Sen_HK
dc.contributor.authorLin, Yen_HK
dc.contributor.authorChen, Men_HK
dc.contributor.authorKou, Zen_HK
dc.contributor.authorHe, Yen_HK
dc.contributor.authorLustigman, Sen_HK
dc.contributor.authorJiang, Sen_HK
dc.contributor.authorZheng, BJen_HK
dc.contributor.authorZhou, Yen_HK
dc.date.accessioned2011-07-27T01:31:07Z-
dc.date.available2011-07-27T01:31:07Z-
dc.date.issued2010en_HK
dc.identifier.citationVaccine, 2010, v. 28 n. 44, p. 7233-7240en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/135278-
dc.description.abstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.en_HK
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.subjectASP-1en_HK
dc.subjectH5N1en_HK
dc.subjectM2een_HK
dc.subjectVaccineen_HK
dc.subject.meshAdjuvants, Immunologic - administration and dosage - pharmacology-
dc.subject.meshAntigens, Helminth - administration and dosage - immunology-
dc.subject.meshHelminth Proteins - administration and dosage - immunology-
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology-
dc.subject.meshInfluenza Vaccines - immunology-
dc.titleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvanten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=28&issue=44&spage=7233&epage=7240&date=2010&atitle=Induction+of+protection+against+divergent+H5N1+influenza+viruses+using+a+recombinant+fusion+protein+linking+influenza+M2e+to+Onchocerca+volvulus+activation+associated+protein-1+(ASP-1)+adjuvant-
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2010.08.049en_HK
dc.identifier.pmid20732469-
dc.identifier.scopuseid_2-s2.0-77957821697en_HK
dc.identifier.hkuros188636en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77957821697&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume28en_HK
dc.identifier.issue44en_HK
dc.identifier.spage7233en_HK
dc.identifier.epage7240en_HK
dc.identifier.isiWOS:000283980400015-
dc.publisher.placeUnited Kingdomen_HK
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza-
dc.relation.projectCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice-
dc.identifier.scopusauthoridZhao, G=8684553000en_HK
dc.identifier.scopusauthoridDu, L=8686996200en_HK
dc.identifier.scopusauthoridXiao, W=9245533300en_HK
dc.identifier.scopusauthoridSun, S=35171536200en_HK
dc.identifier.scopusauthoridLin, Y=23479885500en_HK
dc.identifier.scopusauthoridChen, M=35168778400en_HK
dc.identifier.scopusauthoridKou, Z=23034818200en_HK
dc.identifier.scopusauthoridHe, Y=8742157400en_HK
dc.identifier.scopusauthoridLustigman, S=7003666182en_HK
dc.identifier.scopusauthoridJiang, S=7404453146en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridZhou, Y=8791655300en_HK
dc.identifier.citeulike7716681-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats